Viking Therapeutics, Inc. (NASDAQ:VKTX) is gearing up to initiate a phase 3 study using its subcutaneous formulation of its candidate VK2735 for the treatment of patients with obesity. It is ...

Q1 2025 Management View CEO Brian Lian highlighted the company's progress in advancing its VK2735 obesity program, with Phase ...

Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Viking Therapeutics (NASDAQ: VKTX), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was ...

Viking Therapeutics saw its stock rise by 11% over ... The company's completion of subject enrollment for the Phase 2 clinical trial of VK2735, targeting weight loss, and promising results from ...

Viking Therapeutics stock climbed higher in March after the company released the results from its 13-week study for its GLP-1 candidate VK2735. The study showed that participants achieved 13.1% ...

Shares of Viking Therapeutics (NASDAQ ... "Our thesis is entirely focused on lead [injectable] drug, VK2735, a GLP-1/GIP dual agonist entering phase 3 development for general obesity." ...

Viking Therapeutics saw its stock rise by 11% over the last week, coinciding with significant developments in its clinical trials. The company's completion of subject enrollment for the Phase 2 ...